VRTX monthly performance report
View VRTX's monthly returns, drawdown, and seasonality trends — updated every month.
VRTX monthly report
—
Key takeaways
- Vertex Pharmaceuticals (VRTX) closed November 2026 at $538.60, down 3.63% for the month and +23.95% over the trailing 12 months.
- Year-to-date, VRTX is +18.80%, outperforming the S&P 500 which has returned +10.62% YTD.
- The stock is trading +11.39% versus its 200-day moving average ($483.54), a bullish technical signal.
- Over the past three years, VRTX has underperformed the S&P 500 by −29.23%, with a relative strength index reading of 82.9.
- Win rate over the trailing 39 months stands at 61.5% — 24 positive months versus 15 negative months.
Vertex Pharmaceuticals ended November 2026 at $538.60, posting a monthly return of −3.63%. The S&P 500 returned −0.18% over the same window, leaving relative performance at −3.45%.
The current quarter stands at +3.02% (Q4 2026 (QTD)), while medium-term trend remains constructive: price is +11.39% versus the 200-day moving average ($483.54).
Year-to-date, VRTX is +18.80% against SPY +10.62%, a gap of +8.18%. The stock is currently −5.29% below its 52-week high, with maximum 3-year drawdown at −29.07%.
| Period | VRTX | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −0.74% | −0.36% | −0.38% |
| 1 Week | −1.55% | +2.59% | −4.15% |
| 1 Month | −3.63% | −0.18% | −3.45% |
| 3 Months | +4.47% | −2.37% | +6.84% |
| 6 Months | +19.58% | +0.83% | +18.75% |
| YTD | +18.80% | +10.62% | +8.18% |
| 12 Months | +23.95% | +12.25% | +11.70% |
| 3 Years | +42.14% | +71.37% | −29.23% |
| Rank | Month | Return |
|---|---|---|
| #1 | May 2024 | +15.92% |
| #2 | Dec 2023 | +14.68% |
| #3 | Jan 2025 | +14.65% |
| #4 | Aug 2026 | +14.13% |
| #5 | Jun 2026 | +10.99% |
| Rank | Month | Return |
|---|---|---|
| #1 | Aug 2025 | −14.41% |
| #2 | Dec 2024 | −13.98% |
| #3 | May 2025 | −13.24% |
| #4 | Mar 2026 | −10.12% |
| #5 | Sep 2024 | −6.21% |
| Quarter | Return |
|---|---|
| Q3 2025 | −12.03% |
| Q4 2025 | +15.76% |
| Q1 2026 | −1.50% |
| Q2 2026 | +11.24% |
| Q3 2026 | +5.25% |
| Q4 2026 (QTD) | +3.02% |
| Year | Return |
|---|---|
| 2023 | +40.90% |
| 2024 | −1.03% |
| 2025 | +12.58% |
| 2026 | +18.80% |
| Metric | Value |
|---|---|
| 52-Week High | $568.67 (2026-11-02) |
| 52-Week Low | $412.27 (2026-05-05) |
| Current Price | $538.60 |
| 200-Day Moving Average | $483.54 |
| Price vs 200DMA | +11.39% |
| 3-Year Maximum Drawdown | −29.07% (2025-08-08) |
| Current Drawdown from 52W High | −5.29% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 82.9 |
| 3-Year Excess Return vs S&P 500 | −29.23% |
| RS Peak | 110.5 (Apr 2025) |
| RS Trough | 65 (Jun 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was VRTX's return for this report period?
VRTX returned −3.63% in the latest monthly window ending 2026-11-13.
Has VRTX outperformed SPY year to date?
YTD VRTX: +18.80% vs SPY: +10.62%.
What is VRTX's 12-month return?
+23.95% over the trailing 12 months.
Is VRTX above or below its 200-day moving average?
Price is +11.39% versus 200DMA ($483.54).
What is the maximum drawdown in the 3-year window?
−29.07% on 2025-08-08.